REG - N4 Pharma PLC - Patent Grant and Board Change

N4 PharmaAnnouncement

25/07/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230725:nRSY0209Ha&default-theme=true

RNS Number : 0209H  N4 Pharma PLC  25 July 2023

25 July 2023

N4 Pharma Plc

("N4 Pharma" or the "Company")

 

Patent Grant and Board Change

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing
Nuvec®, a novel delivery system for cancer treatments and vaccines, announces
two operational updates.

Granting of further US patent

The University of Queensland has informed the Company that it has been
notified by the US patent attorney of the granting of its further patent
application in relation to Nuvec® in the United States.

N4 Pharma has licensed the exclusive worldwide rights to Nuvec® from the
University of Queensland for therapeutic uses in humans and animals.

This granted patent in the US is for the composition of matter of the
nanoparticle itself and will sit alongside the first US patent grant announced
on 31 January 2022, which concerned how the nanoparticle is made using a broad
description of the manufacturing process used by the Company.

Board Change

 

The Company announces that John Chiplin, currently Non-Executive Chairman, is
retiring from the Board for personal reasons. Chris Britten, currently a
Non-Executive Director of the Company, will assume the role of Non-Executive
Chairman of N4 Pharma with effect from 1 August 2023.

 

The Company will initiate a search process to identify an additional
Non-Executive Director and will provide an update as and when appropriate.

 

Nigel Theobald, Chief Executive Officer of the Company, commented:

"We are delighted to receive notification of this further patent grant for our
licensed patent in this critical and influential market.

"The granting of this patent now means the patents in the US are on equal
terms to those granted in other territories for both the particle itself and
how it is made.

 

"On behalf of the Board, I would like to thank John for his contributions as
Chairman of the Company over the last few years and we wish him all the best
for the future."

 

 

 

Enquiries:

 N4 Pharma Plc                                          Via IFC Advisory

 Nigel Theobald, CEO

 Luke Cairns, Executive Director

 SP Angel Corporate Finance LLP                         Tel: +44 (0)20 3470 0470

 Nominated Adviser and Joint Broker

 Matthew Johnson/Kasia Brzozowska (Corporate Finance)

 Vadim Alexandre/Rob Rees (Corporate Broking)

 Turner Pope Investments (TPI) Limited                  Tel: +44 (0)20 3657 0050

 Joint Broker

 Andy Thacker

 IFC Advisory Limited                                   Tel: +44 (0)20 3934 6630

 Financial PR

 Graham Herring

 Zach Cohen

 

 

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery
system for cancer and vaccine treatments using its unique silica nanoparticle
delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel
antigens for cancer and vaccine treatments to use Nuvec® as the delivery
vehicle to get their antigen into cells to express the protein needed for the
required immunity. As these products progress through pre-clinical and
clinical programs, N4 Pharma will seek to receive upfront payments, milestone
payments and ultimately royalty payments once products reach the market.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCNKQBDOBKDOOB